Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS) (FerMDS)
Myelodysplastic Syndromes, Ferroptosis
About this trial
This is an interventional diagnostic trial for Myelodysplastic Syndromes
Eligibility Criteria
Inclusion Criteria: For all : Patients of legal age (age ≥ 18 years) Subjects affiliated to or benefiting from a social security scheme Free, written and informed consent signed by the participant and the investigator For MDS patients : Sampling at diagnosis for MDS patients (WHO 2016 criteria) Presence of ring sideroblasts on bone marrow smear For MGUS patients : - Sampling as part of the exploration of monoclonal gammopathy of undetermined significance (MGUS) for controls (WHO 2016 criteria). Exclusion Criteria: For all Patient transfused with red blood cells within 120 days prior to collection Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda Person under a legal protection measure (legal protection, guardianship or curatorship) Person deprived of liberty by judicial or administrative decision Person who is unable to give consent Subject who is in an exclusion period after another study or who has participated in another interventional drug study within 30 days prior to entry into the protocol
Sites / Locations
- CHU de Bordeaux, Laboratoire d'Hématologie
- CHU de Bordeaux, Service de Médecine Interne
- CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
SF3B1 mutant Myelodysplastic syndromes patients (MDS)
Monoclonal Gammapathy of Unknown Significance patients (MGUS)
Patients diagnosed with MDS carrying the SF3B1 somatic mutation associated myelodysplastic neoplasm with ring sideroblasts
MGUS patients, referred to as normal bone marrow controls